Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

29.36
-1.1600-3.80%
Post-market: 29.610.2500+0.85%19:30 EDT
Volume:1.35M
Turnover:38.91M
Market Cap:1.10B
PE:-29.38
High:30.90
Open:30.73
Low:27.00
Close:30.52
52wk High:54.85
52wk Low:27.00
Shares:37.49M
Float Shares:28.93M
Volume Ratio:2.37
T/O Rate:4.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9993
EPS(LYR):-0.1400
ROE:-116.07%
ROA:-0.45%
PB:72.41
PE(LYR):-209.71

Loading ...

Harrow Price Target Maintained with a $63.00/Share by BTIG

Dow Jones
·
Oct 07

Analysts’ Top Healthcare Picks: GE Healthcare Technologies Inc (GEHC), Harrow Health (HROW)

TIPRANKS
·
Oct 05

Lake Street Keeps Their Buy Rating on Harrow Health (HROW)

TIPRANKS
·
Oct 05

Harrow Closes Tyrvaya Nasal Spray Acquisition from Viatris for USD 30 Million Upfront

Reuters
·
Oct 05

Harrow Closes Acquisition of Tyrvaya®

THOMSON REUTERS
·
Oct 05

Harrow to Present Phase 3 Byqlovi Post-Cataract Inflammation Trial Data at AAO 2026

Reuters
·
Sep 30

Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)

TIPRANKS
·
Sep 30

Leerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price Target

MT Newswires Live
·
Sep 09

Harrow initiated with an Outperform at Leerink

TIPRANKS
·
Sep 09

Harrow CFO Andrew Boll Takes on Principal Accounting Officer Role After Pollard Exit

Reuters
·
Sep 05

Harrow (HROW) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 28

Analysts’ Top NA Picks: Harrow Health (HROW), Boost Run (BRUN)

TIPRANKS
·
Aug 26

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

TIPRANKS
·
Aug 20

Analysts Have Conflicting Sentiments on These NA Companies: Harrow Health (HROW) and Lineage, Inc. (LINE)

TIPRANKS
·
Aug 20

Harrow's IHEEZO Cuts Patient-Reported Discomfort 58% in Intravitreal-Injection Study

MT Newswires Live
·
Aug 20

Harrow Announces Iheezo® Data in Patient-Reported Discomfort Following Intravitreal Injections

THOMSON REUTERS
·
Aug 20

Harrow: Single-Center, Investigator-Initiated Study Demonstrated Statistically Significant Differences Favoring Iheezo at Every Measured Time Point

THOMSON REUTERS
·
Aug 20

Harrow - Iheezo Associated with Lower Patient-Reported Discomfort at All Post-Injection Assessments

THOMSON REUTERS
·
Aug 20

Harrow Says Iheezo Trial Shows 58% Lower Discomfort than Proparacaine After Intravitreal Injections

Reuters
·
Aug 20

Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 20